CCL2 and autosomal dominant polycystic kidney disease: Studies have demonstrated that measurement of urinary MCP-1 has potential as a biomarker for diagnosis, prognosis and response to therapy in a variety of renal diseases including diabetic nephropathy, lupus nephritis, ANCA- associated vasculitis, and autosomal dominant polycystic kidney disease (ADPKD) [18–22].